Homepage
Healthcare · Medical - Pharmaceuticals · United States · Updated May 10, 6:13pm
$1.22
Price
$34.2M
Market Cap
11
Employees
1.42
Beta
James Brian Windsor
CEO
Business Description
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.62
Stock Price: $1.22
EPS (Diluted): -1.96
EPS (Diluted): -1.96
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
1.74
Stock Price: $1.22
Total Equity: $16.92M
Shares: 25,444,795
Total Equity: $16.92M
Shares: 25,444,795
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-1.36
Market Cap: $34.21M
Total Debt: $0.00
Cash: $3.22M
EBITDA: -$21.93M
Total Debt: $0.00
Cash: $3.22M
EBITDA: -$21.93M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$26.3M
Market Cap: $34.21M
Total Debt: $0.00
Cash: $3.22M
Total Debt: $0.00
Cash: $3.22M
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: -$1,000
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$21.93M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$49.87M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-281.0%
Net Income: -$49.87M
Total Equity: $16.92M
Total Equity: $16.92M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-120.3%
Operating Income: -$21.93M
Tax Rate: 1.4%
Equity: $16.92M
Total Debt: $0.00
Cash: $3.22M
Tax Rate: 1.4%
Equity: $16.92M
Total Debt: $0.00
Cash: $3.22M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
0.70
Current Assets: $4.33M
Current Liabilities: $6.18M
Current Liabilities: $6.18M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $16.92M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $16.92M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 25,444,795
Shares: 25,444,795
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$0.66
Total Equity: $16.92M
Shares: 25,444,795
Shares: 25,444,795
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-0.76
Operating CF: -$19.36M
CapEx: $0.00
Shares: 25,444,795
CapEx: $0.00
Shares: 25,444,795
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $1.22
Stock Price: $1.22
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$49.87M
Net Income: -$49.87M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares RNTX against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 | $1,000 |
| Gross Profit | $0 | $0 | $0 | $0 | $-1,000 |
| Operating Expenses | $26,605 | $27,647 | $16,276 | $65.1M | $21.9M |
| Operating Income | $-26,605 | $-27,647 | $-16,276 | -$65.1M | -$21.9M |
| Net Income | $-26,164 | $-27,329 | $-15,732 | -$62.9M | -$49.9M |
| EBITDA | $-26,484 | $-27,478 | $-15,229 | -$28.0M | -$21.9M |
| EPS | $-5.89 | $-6.02 | $-3.42 | $-3.51 | $-1.96 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $3.6M | $5.2M | $17.3M | $12.9M | $3.2M |
| Total Current Assets | $48.2M | $21.9M | $18.3M | $13.7M | $4.3M |
| Total Assets | $48.5M | $22.0M | $106.0M | $69.2M | $24.2M |
| Current Liabilities | $4.5M | $3.4M | $4.4M | $5.7M | $6.2M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $4.6M | $3.4M | $99.1M | $14.8M | $7.2M |
| Total Equity | $43.9M | $18.6M | $6.9M | $54.4M | $16.9M |
| Retained Earnings | -$245.5M | -$272.8M | -$288.5M | -$351.4M | -$401.3M |
Cash Flow (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$23.8M | -$24.9M | -$19.8M | -$22.3M | -$19.4M |
| Capital Expenditure | $-157,000 | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$23.9M | -$24.9M | -$19.8M | -$22.3M | -$19.4M |
| Acquisitions (net) | $0 | $0 | $-96,000 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$4.0M | $1.6M | $12.1M | -$4.5M | -$9.7M |
Analyst Estimates (Annual)
| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$127.7M $127.7M – $127.7M
|
$0 | $0 |
$144.1M $144.1M – $144.1M
|
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$33.8M -$33.8M – -$33.8M
|
-$37.1M -$37.1M – -$37.1M
|
-$31.0M -$31.0M – -$31.0M
|
$10.9M $10.9M – $10.9M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | -3.9% | +41.1% | -399,949.2% | +66.3% |
| Net Income Growth | -4.5% | +42.4% | -399,614.0% | +20.7% |
| EBITDA Growth | -3.8% | +44.6% | -184,081.5% | +21.8% |
Insider Trading (Recent)
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2025-11-14 | Voss Capital, LP | P-Purchase | 104,183.00 | $1.22 | $127,593 |
| 2025-10-27 | Voss Capital, LP | P-Purchase | 92,642.00 | $1.37 | $126,920 |
| 2025-10-24 | Voss Capital, LP | P-Purchase | 30,176.00 | $1.39 | $41,957 |
| 2025-10-28 | Voss Capital, LP | P-Purchase | 178,392.00 | $1.39 | $247,965 |
| 2025-10-27 | Voss Capital, LP | P-Purchase | 4,840.00 | $1.37 | $6,625 |
| 2025-09-24 | Voss Capital, LP | 0.00 | $0.00 | $0 | |
| 2025-09-24 | Voss Capital, LP | 0.00 | $0.00 | $0 | |
| 2025-07-23 | Aivado Manuel | A-Award | 17,500.00 | $1.55 | $27,125 |
| 2025-07-23 | VON RICKENBACH JOSEF H | A-Award | 17,500.00 | $1.55 | $27,125 |
| 2025-07-23 | Musso Alan A | A-Award | 17,500.00 | $1.55 | $27,125 |
| 2025-07-23 | Fairey William | A-Award | 17,500.00 | $1.55 | $27,125 |
| 2025-07-23 | Ambros Reinhard J. | A-Award | 17,500.00 | $1.55 | $27,125 |
No community reviews yet for RNTX.
Be the first — export the analysis to your AI and contribute back.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.193 · 1946f027 · 2026-05-08 18:57:27